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demic clones in the United Kingdom, and responds differently to a
control measure based on a surface antiseptic protocol.
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Kala-azar or visceral leishmaniasis affects the poorest of the
oor in the Indian sub-continent. It is almost always fatal if
ntreated. Till a decade agopentavalent antimonials, used since the
940s, continued to be in use in spite of having high toxicity and
mergence of parasite resistance in India. In the last decade several
ew drugs have become available in the treatment of kala-azar,
amely miltefosine, paromomycin and liposomal amphotericin B.
oth miltefosine, the only oral drug, and paromomycin require
rolonged therapy directly observed therapy for 4 and 3 weeks
espectively which is difﬁcult to organise in the remote regions.
lso miltefosine is contra-indicated in pregnancy and in women of
hildbearingageunless theyusecontraceptionwhileparomomycin
equires daily injections. Recent approaches have targeted devel-
pment of shorter combination regimens lasting 7 to 10 days
miltefosine plus paromomycin; liposomal amphotericin B and
iltefosine; liposomal amphotericin B and paromomycin) and a
ingle-dose liposomal amphotericin B (10 mg/kg) with excellent
fﬁcacy and safety in clinical trials. These shorter regimens in addi-
ion to assuring good compliance will also protect individual drugs
rom developing resistance in the long term. Currently large scale
ublic health studies of these regimens are underway in the Indian
ub-continent to help introduce them at the primary health centre
evel.
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ala-azar elimination - Monitoring and evaluation
. Rahman
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Kala-azar is one of the most neglected tropical diseases affect-
ng the three endemic countries of this region, Bangladesh, India
nd Nepal. Approximately 200 million people in 109 districts of
hese countries are “at risk”. Bangladesh, India and Nepal have
ommitted themselves to collaborate in efforts to eliminate kala-
zar from the South-East Asia Region by 2015. In May 2005, the
hree countries signed a Memorandum of Understanding (MoU) in
enevaduring theWorldHealthAssembly, committing themselves
o mutual cooperation towards elimination of kala-azar from the
espective countries. A Regional Strategic Plan has been preparednfectious Diseases 16S (2012) e2–e157 e53
and endorsed by the WHO-SEARO Regional Technical Advisory
Group (RTAG) and partners supporting elimination of kala-azar.
Bangladesh situation: Kala-azar is a re-emerging disease and
a public health problem in Bangladesh. Kalaazar almost disap-
peared during the ‘Malaria Eradication Programmme (1961-1970).
At present Kala-azar cases are reported from139 upazilas in 45 dis-
tricts of Bangladesh. Poorest of the poor people are suffering from
the disease. On an average 10,000 cases are detected and treated
annually. Present disease surveillance is weak and the estimated
prevalence is 45,000 cases. In 1981 only 8 upazila reported Kala-
azar, which has increased to 139 upazila in 45 districts by 2008.
Cumulative 58,093 cases and 189 deathswere reported since 2000-
2008. In 2010, 2763 cases and 1deaths were reported. More than
half of total cases (54%) are from Mymensingh district. Another
three districts Pabna, Tangail and Jamalpur will add 25% cases.
Goal and process: Kalaazar Elimination program has been ini-
tiated to contribute to improving the health status of vulnerable
groups and at-risk population living in kala-azar-endemic areas of
Bangladesh, India and Nepal with a speciﬁc target to reduce the
annual incidence of kala-azar to less than one per 10,000 popula-
tion by 2015, reduce case fatality rates and prevent the emergence
of Kala azar/HIV, and TB co-infections.
For monitoring and evaluation 42 indicators have been iden-
tiﬁed on Policy, strategy and advocacy plans, coordination
mechanism, capacity building in case detection and management.
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Transmission dynamics of MRSA in Asia
B. Cooper
Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand
ThedominantMRSAsequence type (ST) inAsia is ST239, and this
ST has distinct lineages in Asia, Europe and South America which
probably share a European ancestor. Little is known about what
has enabled this ST to be so successful, or whether its propensity
to transmit between hosts differs from other MRSA types in certain
settings.
In this talk I present results of analyses of two highly detailed
studies of MRSA ST239 transmission: the ﬁrst comes from two
intensive care units in a regional hospital in Northeast Thailand,
and the second from an outbreak of an Asian ST239 lineage in two
intensive care units in a teaching hospital in the United Kingdom. I
showhownew analytical approaches andwhole genome sequence
data allow the study of the transmission dynamics of this organism
at unprecedented levels of detail, and discuss evidence that this
lineagehas an enhanced transmissibility compared to endemic epi-
